These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 16513623)

  • 61. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Renal accumulation of [111In]DOTATOC in rats: influence of inhibitors of the organic ion transport and diuretics.
    Stahl AR; Wagner B; Poethko T; Perutka M; Wester HJ; Essler M; Heemann U; Schwaiger M; Lutz J
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2129-34. PubMed ID: 17694308
    [TBL] [Abstract][Full Text] [Related]  

  • 63. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
    Decristoforo C; Melendez-Alafort L; Sosabowski JK; Mather SJ
    J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results.
    Maina T; Nock B; Nikolopoulou A; Sotiriou P; Loudos G; Maintas D; Cordopatis P; Chiotellis E
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):742-53. PubMed ID: 12029547
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys.
    Kopecky M; Semecky V; Trejtnar F; Laznicek M; Laznickova A; Nachtigal P; Decristoforo C; Mather SJ; Mäcke HR
    Nucl Med Biol; 2004 Feb; 31(2):231-9. PubMed ID: 15013489
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats.
    Laznickova A; Laznicek M; Trejtnar F; Maecke HR; Eisenwiener KP; Reubi JC
    Anticancer Res; 2010 Jun; 30(6):2177-84. PubMed ID: 20651367
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Biokinetics of 111In-DTPA-D-Phe(1)-octreotide in nude mice transplanted with a human carcinoid tumor.
    Bernhardt P; Kölby L; Johanson V; Benjegård SA; Nilsson O; Ahlman H; Forssell-Aronsson E
    Nucl Med Biol; 2001 Jan; 28(1):67-73. PubMed ID: 11182566
    [TBL] [Abstract][Full Text] [Related]  

  • 68. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
    Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
    Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
    Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
    Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
    Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
    Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
    Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes.
    Duncan JR; Stephenson MT; Wu HP; Anderson CJ
    Cancer Res; 1997 Feb; 57(4):659-71. PubMed ID: 9044843
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide: preliminary report in cancer patients.
    Paganelli G; Zoboli S; Cremonesi M; Mäcke HR; Chinol M
    Cancer Biother Radiopharm; 1999 Dec; 14(6):477-83. PubMed ID: 10850334
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
    Reilly RM; Chen P; Wang J; Scollard D; Cameron R; Vallis KA
    J Nucl Med; 2006 Jun; 47(6):1023-31. PubMed ID: 16741313
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Potential Biomarkers for Radiation-Induced Renal Toxicity following 177Lu-Octreotate Administration in Mice.
    Schüler E; Larsson M; Parris TZ; Johansson ME; Helou K; Forssell-Aronsson E
    PLoS One; 2015; 10(8):e0136204. PubMed ID: 26287527
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.
    Laznickova A; Laznicek M; Trejtnar F; Melicharova L; Suzuki KH; Akizawa H; Arano Y; Yokoyama A
    Eur J Drug Metab Pharmacokinet; 2002; 27(1):37-43. PubMed ID: 11996325
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences.
    Melis M; Krenning EP; Bernard BF; de Visser M; Rolleman E; de Jong M
    Nucl Med Biol; 2007 Aug; 34(6):633-41. PubMed ID: 17707803
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours.
    Forrer F; Mueller-Brand J; Maecke H
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):511-2; author reply 513. PubMed ID: 15688195
    [No Abstract]   [Full Text] [Related]  

  • 79. Evaluation in vitro and in rats of 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy.
    de Jong M; Breeman WA; Bernard BF; Rolleman EJ; Hofland LJ; Visser TJ; Setyono-Han B; Bakker WH; van der Pluijm ME; Krenning EP
    Eur J Nucl Med; 1995 Jul; 22(7):608-16. PubMed ID: 7498221
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
    Merlo A; Hausmann O; Wasner M; Steiner P; Otte A; Jermann E; Freitag P; Reubi JC; Müller-Brand J; Gratzl O; Mäcke HR
    Clin Cancer Res; 1999 May; 5(5):1025-33. PubMed ID: 10353735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.